

# Contraception After Gestational Diabetes

PETER DAMM, MD, DMSC<sup>1</sup>  
ELISABETH R. MATHIESEN, MD, DMSC<sup>2</sup>

KRESTEN R. PETERSEN, MD, DMSC<sup>3</sup>  
SIRI KJOS, MD<sup>4</sup>

**W**omen with prior gestational diabetes mellitus (GDM) are at risk of developing overt diabetes, predominantly type 2 diabetes, after pregnancy, often during their reproductive years (1–4). Type 2 diabetes will often be present without symptoms years before the clinical diagnosis is made. Women with type 2 diabetes often do not plan their pregnancy (5) or enter pregnancy with unrecognized diabetes. In both cases, an increased risk of congenital malformations in the offspring has been found (5–7). Similar to type 1 diabetes, this risk has been shown to increase with increasing maternal hyperglycemia (8). Although intervention trials are lacking in type 2 diabetic women, studies in type 1 diabetic women have shown that the proportion of congenital malformations can be reduced to a background population value by prepregnancy planning, including optimization of metabolic control (8). Contraception is an essential component to be able to plan pregnancy when glucose status is normalized and may also confer protection from developing diabetes by preventing a subsequent pregnancy (9). Recent studies show that women with previous GDM exhibit a markedly increased prevalence of the metabolic syndrome, even when glucose tolerance is normal (10,11). Metabolic syndrome is associated with an increased risk of cardiovascular disease and mortality (12).

For both maternal and future offspring, women with prior GDM need safe, efficient, and acceptable choices for contraceptive methods that do not enhance their already substantial risk to develop

either overt diabetes or metabolic syndrome and associated sequelae.

Studies on contraception in women with prior GDM are limited, especially new studies published since the Fourth International Workshop-Conference on GDM (13). The present article provides a condensed review of contraceptive methods available for women with prior GDM, focusing on recent studies. When data in women with prior GDM are unavailable, extrapolations will be made from studies in healthy women or from women with diabetes, either type 1 or type 2, who are presumed to have a higher risk of possible complications from contraceptive methods. In all cases, risks of contraception should be compared with pregnancy risk, wanted and unwanted, and risks to future offspring and mother.

**BARRIER METHODS**— Barrier methods, which include condoms, diaphragm, cervical cap, and spermicides, are well suited for women with prior GDM because of their lack of systemic side effects or influence on glucose tolerance. The typical use annual rate of failure for these methods is in the 20% range. Strong patient and partner motivation and careful instruction detailing proper use may improve contraceptive success. If these criteria cannot be met, intrauterine or hormonal contraception may be better alternatives. The use of condoms should be encouraged in all women with previous GDM who appear at risk for sexually transmitted diseases and human immunodeficiency virus.

**INTRAUTERINE DEVICES**— The intrauterine device (IUD) is a very effective and reversible contraceptive method without metabolic disturbances and therefore is an ideal contraceptive for women with prior GDM. The 2004 World Health Organization Medical Eligibility Criteria for Contraceptive Use (14) report does not consider prior GDM as a contraindication to IUD prescription. Currently, marked IUDs predominantly contain either copper or levonorgestrel and have not been associated with any increased risk of pelvic inflammatory disease. Both offer excellent pregnancy protection with failure rates below 1%. Their safety is reaffirmed by studies in women with type 1 (15,16) or type 2 (17) diabetes using copper releasing IUDs, which showed no increased risk of pelvic inflammatory disease or failure. The World Health Organization report lists no restrictions on IUD use in either type 1 or type 2 diabetes. The levonorgestrel-releasing IUDs may prove to become a very important contraceptive method for women with a history of GDM because of the very high contraceptive efficacy and the low frequency of bleeding disturbances (18). Furthermore, menstrual bleeding is reduced by progestin-mediated atrophy of the uterine lining, which theoretically would be beneficial in obese glucose-intolerant relatively older and parous women, characteristics common in women with prior GDM. The hormonal release from levonorgestrel-releasing IUDs is low and does not cause significant metabolic effects in normal women (19). So far, no studies have been published with data on the use of levonorgestrel-releasing IUDs in women with a history of GDM. However, a recent randomized trial of the use in women with type 1 diabetes did not show any influence on blood glucose, A1C, or daily insulin dose (20). Therefore, based on the existing evidence, both copper and levonorgestrel-releasing IUDs can be used safely and without any specific restrictions in women with a history of GDM and may be continued if they develop diabetes.

**COMBINATION ORAL CONTRACEPTIVES**— Combination oral contraceptives (COCs) contain estrogen and progestin and are the most widely

From the <sup>1</sup>Obstetric Clinic, Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the <sup>2</sup>Endocrinologic Clinic, Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the <sup>3</sup>Department of Obstetrics and Gynecology, University Hospital of Odense, Odense, Denmark; and the <sup>4</sup>Department of Obstetrics and Gynecology, Harbor-University of California Los Angeles Medical Center, Torrance, California.

Address correspondence and reprint requests to Peter Damm, MD, DMSc, Obstetric Clinic 4031, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E-mail: pdamm@dadlnet.dk.

Received for publication 15 June 2006 and accepted in revised form 28 November 2006.

This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from LifeScan, Inc., a Johnson & Johnson company.

**Abbreviations:** COC, combination oral contraceptive; DMPA, depo-medroxyprogesterone acetate; GDM, gestational diabetes mellitus; IUD, intrauterine device; POC, progestin-only oral contraceptive.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

DOI: 10.2337/dc07-s222

© 2007 by the American Diabetes Association.

Table 1—Metabolic effects of hormonal contraceptive methods and components

	Oral estrogen	Oral progestin	Intramuscular and implants of progestin	IUD
Glucose tolerance	Neutral	↑ Insulin resistance ↑ Glucose tolerance	↑ Insulin resistance ↑ Glucose tolerance	Neutral
Lipids	↑ HDL cholesterol ↓ LDL cholesterol ↑ Triglyceride	↓ HDL cholesterol ↓ LDL cholesterol ↓ Triglyceride	Variable on HDL cholesterol ↓ Triglyceride	Neutral
Blood pressure	Slight ↑	Neutral	Neutral	Neutral
Coagulation	↑ Globulins: dose-dependent ↑	Neutral	Neutral	Neutral

The net effect of COCs varies depending on the various amounts and components of estrogen and progestin used. See text for details.

used type of hormonal contraception. While the estrogen component is always ethinyl estradiol, the type and dose of progestin varies. Generally, ethinyl estradiol has no net effect on glucose tolerance and insulin sensitivity (21) but even the lowest ethinyl estradiol dosage may adversely influence hemostatic and renin-angiotension systems to increase thrombosis risk and blood pressure (22). Ethinyl estradiol also affects lipid metabolism, increasing triglycerides and HDL cholesterol levels and decreasing LDL cholesterol (22,23). The metabolic effects are dose dependent with respect to the amount of estrogen used in the COC. The clinical reason for oral contraceptives to contain estrogen is to improve bleeding control, thereby improving patient compliance. It is important to use the lowest dose possible, or “low-dose COCs” containing 20–35  $\mu\text{g}$ —doses that have proven sufficient to maintain satisfactory cycle control.

The progestin components most widely used in today's COCs are either “second-generation” (e.g., levonorgestrel or norgestimate) or “third-generation” (e.g., desogestrel or gestoden). The third-generation progestins have less androgenic side effects. Progestins decrease glucose tolerance and insulin sensitivity. Importantly, progestins have no influence on blood pressure or clotting factors; they may however modify the effects of estrogen by mechanisms still to be elucidated. The progestin effect on lipids tends to antagonize the estrogen effect, i.e., lowering of triglycerides and HDL cholesterol and increasing LDL cholesterol (22,23). The metabolic effects of a given COC formulation will therefore depend on the net effect of the type and/or dosage of each hormonal component. Today's COCs tend to be estrogen dominant. In healthy

populations, epidemiological studies in current or previous COC users have not demonstrated an increased risk to develop diabetes (24). Short-term studies have found no clinically relevant detrimental effect on lipid metabolism, and newer COC formulations actually demonstrate a beneficial effect on lipid profiles (22,23). Table 1 outlines the metabolic effects of COCs.

### Epidemiological studies

Recent epidemiological case-control studies show that, compared with nonusers, low-dose COC users have an increase in risk of venous and cerebral thrombotic episodes and myocardial infarction (25). A recent large meta-analysis (25) including 14 studies found that current COC users had a twofold increase in summary odds ratio for myocardial infarct and ischemic stroke. Second-generation COCs significantly increased the risk of both arterial events, whereas third-generation COCs continued to increase the risk of ischemic stroke. Compared with nonusers, past use of COCs appeared to be protective of both events. When corrected for other cardiovascular risk factors, the increased risk with COC use persisted. Hypertension, smoking, diabetes, lipid abnormalities, obesity, and family history of arterial events were associated each with an approximate twofold increase in myocardial infarction and a two- to threefold increase in ischemic stroke.

In a second meta-analysis specifically examining COC use in women with pre-existing disease, the presence of hypertension per se was associated with substantial risk of cardiovascular events (26). Compared with normotensive nonusers, hypertension without COC use was associated with a 5- to 10-fold increased risk of cardiovascular events, after adjust-

ing other risk factors (i.e., diabetes, lipids, obesity, and smoking). Hypertension with COC use further increased the risk 15- to 68-fold, with the large variation in risk likely due to national differences in screening and treatment of hypertension. Similar to hypertension, COC use in women with a history of migraine was associated with a two- to fourfold increase in stroke compared with nonusers with migraine (26).

The ethinyl estradiol dose in the COC formulation appears to be of greater importance for thrombotic risk than the generation of progestin. A recent population study from Denmark found the risk of cerebral thrombosis with current COC use decreased with decreasing estrogen content and with longer duration of use (27). Compared with nonusers, COCs with decreasing ethinyl estradiol doses of 50, 30–40, 20, and 0  $\mu\text{g}$  (progestin-only oral contraceptive) had corresponding decreasing odds ratios (ORs) of 4.5, 1.6, 1.7, and 1.0 for cerebral thrombosis. The stroke risk was greatest during the first year of use (OR 2.7), decreasing at 1–5 years (OR 2.0) and >5 years (OR 1.8). Theoretically, this decrease in risk might be caused if women susceptible to stroke experienced this soon after starting COCs. These researchers found that after adjusting for the ethinyl estradiol dose, the third- to second-generation progestin stroke risk ratio was 0.6. They also found that the adjusted risk (OR 5.6) from diabetes, irrespective of COC use, was approximately half of the crude stroke risk estimate, suggesting that hypertension was a significant contributor to stroke in diabetic women. In their companion study (28) assessing venous thrombotic risk, COC use compared with nonusers increased the risk three- to fourfold. Similarly, this risk was decreased by decreas-

ing ethinyl estradiol dose formulations and longer duration, with the greatest risk during the first year of use (OR 7.0), decreasing to an OR of 3.1 after 5 years of use. The classic arterial risk factors, hypertension, diabetes, hyperlipidemia, and migraine, did not significantly increase the risk of venous thrombotic events.

How does one apply such epidemiological studies to women with a history of GDM? First, the COC-associated risk must be considered in terms of the low absolute risk of cardiovascular and venous thrombotic events in healthy young women (27,28). The majority of women with prior GDM likely fall into this category and low-dose COC can be prescribed, taking into account that the absolute risks increase with age (27,28). Second, one must consider the magnitude of other risk factors, i.e., hypertension, migraine, smoking, hyperlipidemia, coagulation disorders, and family history of thrombosis, which increase the ORs for arterial and venous thrombotic events by 2- to 12-fold in COC users. Baillargeon et al. (25) argued that prospective studies that examine the relation of cardiovascular events and COC are needed in women with polycystic ovarian syndrome, who are insulin resistant, often obese, and have a high prevalence of cardiovascular risk factors. Women with prior GDM often share these same traits. These risks must be weighed against pregnancy, which itself increases the risk of venous thrombosis fivefold (28). A periodic risk assessment of cardiovascular risk factors in women with prior GDM should be done. When hypertension or migraines are present in women with prior GDM, it would be most prudent to not prescribe a COC. In all cases, the lowest ethinyl estradiol dose should be prescribed and close attention should be paid to increases in blood pressure and weight. All women should receive nutritional counseling, be encouraged to exercise daily, achieve a healthy weight, and receive appropriate medical therapy to control blood pressure and/or lipids if lifestyle interventions fail.

### Studies in diabetic women

Short-term studies support low-dose COC prescription in type 1 diabetic women. These studies indicate that the changes in insulin sensitivity, glucose tolerance, lipid metabolism, and the coagulation/thrombotic system are very similar to the findings in healthy women and do not appear to be of clinical significance (22,29). Prescription of COCs does not

appear to increase the risk of developing diabetic retinopathy or nephropathy or worse glycemic control (30,31). One recent study has reported an association between COC use and development of macroalbuminuria in women with diabetes (32). The recommendation has been to avoid COC prescription in diabetic women who smoke, are older (>35 years), or have hypertension or diabetes-related vascular complications (33–36).

Relatively few studies on COC use in women with a history of GDM exist (34). Short-term controlled studies of COC use in both Caucasian and Latino women with a history of GDM have not demonstrated any decrease in glucose tolerance or adverse effects on lipid metabolism (37,38) but have found a slight decrease in insulin sensitivity (39). However, such small metabolic changes do not clinically appear to effect the development of diabetes. In a large prospective observational cohort study of Latino women with prior GDM followed for up to 7 years after pregnancy, COC use was not associated with an increased risk of type 2 diabetes compared with similar women not using hormonal contraception (40). Interestingly, women using COCs had significantly less weight gain than nonusers. This report is in line with population-based studies where COC use has not been identified as a risk factor for type 2 diabetes (35,41). More long-term studies in other populations addressing baseline cardiovascular risk factors and outcomes are needed. Furthermore, it is not possible from the present literature to answer the relevant question if COC use in women with previous GDM affects the risk of developing the metabolic syndrome later in life.

In summary, existing evidence from epidemiological and from limited clinical studies in women with diabetes and prior GDM support the prescription of low-dose COCs in women with a history of GDM. Formulations of COC that contain the lowest dose of ethinyl estradiol and the lowest dose/potency progestin should be prescribed following the same recommendations and precautions for healthy women and women with type 1 diabetes. Strong consideration should be given to non-estrogen-containing methods when coexisting hypertension or other cardiovascular risk factors are present.

### NONORAL COMBINATION HORMONAL METHODS

Recently, non-oral combination hormonal methods have become available and can

be administered as a monthly injection, a transdermal patch, or an intravaginal ring. Epidemiological data regarding safety or detailed metabolic studies are limited in healthy women. Short-term metabolic studies of the contraceptive patch containing ethinyl estradiol and norelgestromin, the primary active metabolite of norgestimate, suggest that its metabolic effect on lipid profiles (42) and serum androgen levels was predominantly estrogenic and similar to low-dose COCs. Minimal changes in serum lipids were found in short-term use of the vaginal ring containing ethinyl estradiol and norethindrone acetate (43). Studies examining coagulation factors or thrombotic risk with either transdermal methods are not available. One case-control study nested in a cohort of women age 15–39 years with polycystic ovarian syndrome, acne, or hirsutism specifically evaluated the risk of venous thromboembolism with either COCs or the monthly injectable combination containing ethinyl estradiol and cyproterone acetate (44). In the cohort, the adjusted incidence thrombosis rate in cyproterone acetate/ethinyl estradiol users was significantly elevated compared with conventional COCs (OR 2.58) and with the referent group of healthy, not recently pregnant, non-OC users (OR 7.44). The authors in their study commented that confounding by prescription indication could not be excluded by their study design. In the absence of specific data relating to GDM, the risks/benefits of non-oral combination methods should be considered similar to those of COCs.

### PROGESTIN-ONLY ORAL CONTRACEPTIVES

Progestin-only oral contraceptives (POCs) are taken continuously and contain low-dose norethindrone or levonorgestrel. Progestins do not increase globulin production; thus, they do not increase coagulation factors or blood pressure (45). Their shortcomings are irregular bleeding and the need to be taken daily at strict time intervals, with no “doubling up” on missed days to be effective. Less epidemiological and clinical data are available, since POCs are less widely prescribed than COCs, largely because of their higher actual use failure rates and breakthrough bleeding rates. They are well suited for women with type 1 diabetes where estrogen-containing methods are contraindicated, since they do not influence diabetes control, hypertension, or other vascular dis-

ease (22,33). They also are well suited for women with prior GDM, who often have several cardiovascular risk factors, making non-estrogen-containing contraceptives desirable. Limited studies exist. In a large cohort study (40) in postpartum Latino women, those who were breastfeeding and therefore prescribed POCs were found to have an adjusted threefold increase in the proportion of development of type 2 diabetes during the first 2 years compared with low-dose COC and nonhormonal methods. The risk was increased with duration of POC exposure. With use  $\leq 4$  months, there was no increased risk, and with 4–8 months and with  $>8$  months use, there was a threefold increased risk and almost a fivefold increased risk of diabetes. Only breastfeeding women were prescribed POCs in the study, and therefore the question of whether non-breastfeeding women with prior GDM also have any increased risk with POC use could not be answered. The authors speculated that the somewhat surprising finding could be a result of a nonphysiological state that suppressed endogenous estrogen levels from lactation, and exogenous administration of unopposed progestin occurred in unique combination with underlying insulin resistance and a  $\beta$ -cell dysfunction, two hallmarks of GDM. These findings have yet to be confirmed in women of other ethnic backgrounds but indicate that progestin-only pills should not be the first choice of contraception for these women during lactation (40). Progestin-only pills may be used in nonlactating women, especially when contraindications for oral contraceptive use (e.g., hypertension) are present.

### LONG-ACTING POC METHODS

— Progestin agents can be administered intramuscularly or subcutaneously as an implant to deliver long-acting and efficacious contraceptive protection. They offer the same metabolic advantage as POC, namely no effect on maternal coagulation factors or blood pressure. There are currently two subcutaneous implants systems: Norplant, with six levonorgestrel rods lasting 5 years, and Implanon, with one etonorgestrel rod lasting 3 years. Norplant is and has been widely used and studied but currently is not marketed in the U.S. Intramuscular progestin compounds include Depo-Provera (depo-medroxyprogesterone acetate [DMPA]), which is given every 3 months, or norethindrone, which is given

monthly. DMPA has in several studies shown to have more adverse effects on lipids and insulin resistance (46–48) compared with the minimal effects with Norplant (49,50); however, metabolic effects of both methods are clinically insignificant in healthy women. Detailed metabolic studies comparing Implanon and Norplant found comparable and nonsignificant changes from baseline in lipid profiles and apolipoproteins over a 3-year period (51). In contrast to implants, return of fertility after discontinuation can be delayed for up to 9 months with DMPA. DMPA also has been associated with greater weight gain.

Use of long-acting progestins in women with diabetes or women at high risk of diabetes is very limited (48). One study in Navajo Indians found that the use of DMPA increases the risk of diabetes (OR 3.6) compared with women using COCs, and this risk was further increased (OR 8.4) with  $>1$  year of use (52). In contrast, the use of COCs was protective for developing diabetes with OR of 0.59 when adjusted for BMI. These findings are similar to a recent study examining contraceptive use in Latino women with prior GDM (53). In this cohort study, women choosing DMPA had an increased risk of developing diabetes (OR 1.58) compared with women who elected to use COCs. However, women who were prescribed DMPA had significantly more risk factors. When baseline imbalances (BMI, breastfeeding, family members with diabetes, HDL cholesterol, and triglycerides) and weight gain during follow-up were adjusted for, there was no excess risk with DMPA use (OR 1.07; 95% CI 0.61–1.89). The increased risk associated with DMPA appeared to be explained by increased baseline diabetes risk, more weight gain during use, and higher baseline triglycerides and/or breastfeeding. The interaction of DMPA with breastfeeding was similar to that of POC with breastfeeding, adversely effecting diabetes risk (40). Thus, DMPA should be used with caution in breastfeeding women and those with elevated triglyceride levels ( $>150$  mg/dl). Close attention should be paid to weight gain, which also has been demonstrated to increase the risk of subsequent diabetes (9). Studies examining the effect of implant systems on diabetes risk in women with prior GDM are lacking.

Overall, long-acting progestin methods are not a first-line choice in women with prior GDM unless compliance with taking daily medication is a problem. If

estrogen-containing contraceptives are contraindicated, the POC would be the first-choice hormonal method or either type of intrauterine device.

### SURGICAL STERILIZATION

— Lastly, operative sterilization is an excellent choice for women who have decided that they no longer are interested in child-bearing. This option should be offered to parous women, especially those delivering by cesarean section, where the sterilization can be performed during the surgical procedure.

**FINAL REMARKS** — Women with prior GDM have many contraceptive options and generally can use all forms of contraception, following essentially the same guidelines as other women. The only significant exception is that progestin-only methods during lactation should be avoided or used with caution. Also, cardiovascular risks and baseline health should be considered when prescribing hormonal methods. In cases of multiple risk factors, a progestin-only method or a metabolically neutral method such as an IUD would be desirable. In all cases, women with prior GDM require effective and safe contraception that suits their lifestyle and does not enhance the risk of developing diabetes, metabolic syndrome, or cardiovascular complications. Regardless of which methods a woman chooses, her care plans should be individualized and should include regular surveillance of glucose tolerance and screening for lipid disorders and other cardiovascular risk factors following standard guidelines. At each visit, blood pressure and weight should be measured and a healthy lifestyle should be reinforced.

### References

1. Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Mølsted-Pedersen L, Hornnes P, Loch H, Pedersen O, Damm P: Increasing incidence of diabetes after gestational diabetes mellitus: a long-term follow-up in a Danish population. *Diabetes Care* 27: 1194–1199, 2004
2. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA: Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. *Diabetes* 44:586–591, 1995
3. Kim C, Newton KM, Knobb RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care* 25:1862–1868, 2002
4. Ratner RE: Prevention of type 2 diabetes

- in women with previous gestational diabetes. *Diabetes Care* 30 (Suppl. 2):S242–S250, 2007
5. Clausen TD, Mathiesen E, Ekblom P, Hellmuth E, Mandrup-Poulsen T, Damm P: Poor pregnancy outcome in women with type 2 diabetes. *Diabetes Care* 28:323–328, 2005
  6. Townner D, Kjos SL, Leung B, Montoro MM, Xiang A, Mestman JH, Buchanan TA: Congenital malformations in pregnancies complicated by NIDDM. *Diabetes Care* 18:1446–1451, 1995
  7. Schaefer UM, Buchanan TA, Songster G, Montoro M, Xiang A, Kjos SL: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes. *Am J Obstet Gynecol* 182:313–320, 2000
  8. Gabbe SG, Graves CR: Management of diabetes mellitus complicating pregnancy. *Obstet Gynecol* 102:857–868, 2003
  9. Peters RK, Kjos SL, Xiang A, Buchanan TA: Long term diabetogenic effect of a single pregnancy in women with previous gestational diabetes mellitus. *Lancet* 347: 227–230, 1996
  10. Verma A, Boney CM, Tucker R, Vohr BR: Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. *J Clin Endocrinol Metab* 87:3227–3235, 2002
  11. Lauenborg L, Mathiesen E, Hansen T, Glümer C, Jørgensen T, Borch-Johnsen K, Hornnes P, Pedersen O, Damm P: The prevalence of the metabolic syndrome in a Danish population of women with previous GDM is 3-fold higher than in the general population. *J Clin Endocrinol Metab* 90:4004–4010, 2005
  12. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 24:683–689, 2001
  13. Kjos SL, Peters RL, Xiang A, Schaefer U, Buchanan TA: Hormonal choices after gestational diabetes: subsequent pregnancy, contraception, and hormone replacement. *Diabetes Care* 21 (Suppl. 2): B50–B57, 1998
  14. World Health Organization: *Medical Eligibility Criteria for Contraceptive Use*. 3rd ed. 2004. [www.who.int/reproductive-health](http://www.who.int/reproductive-health)
  15. Skouby SO, Molsted-Pedersen L, Kosonen A: Consequences of intrauterine contraception in diabetic women. *Fertil Steril* 42:568–572, 1984
  16. Kimmerle R, Heinemann L, Berger M: Intrauterine devices are safe and effective contraceptives for type I diabetic women. *Diabetes Care* 18:1506–1507, 1995
  17. Kjos S, Ballagh SA, La Cour M, Xiang A, Mishekk DR Jr: The copper T380A intrauterine device in women with type II diabetes mellitus. *Obstet Gynecol* 84:1006–1009, 1994
  18. French RS, Cowan FM, Mansour D, Higgins JP, Robinson A, Procter T, Morris S, Guillebaud J: Levonorgestrel-releasing intrauterine systems (Mirena) compared with other methods of reversible contraceptives. *Br J Obstet Gynaecol* 107:1218–1225, 2001
  19. Sturridge F, Guillebaud J: A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. *Drug Saf* 15:430–440, 1996
  20. Rogovskaya S, Rivera R, Grimes DA, Chen P-L, Pierre-Loius B, Prilepskaya V, Kulakov V: Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomised trial. *Obstet Gynecol* 105:811–815, 2005
  21. Spellacy WN, Buih WC, Birk SA: The effect of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred seventy-one women ingesting premarin, mestranol and ethinyl estradiol for six months. *Am J Obstet Gynecol* 114:388–392, 1971
  22. Petersen KR: Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis: studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. *Dan Med Bull* 49:43–60, 2002
  23. Godsland IF, Crook D, Simpson R, Prouddler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. *N Engl J Med* 323:1375–1381, 1990
  24. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, Speizer FE: Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. *Diabetologia* 35: 967–972, 1992
  25. Baillargeon JP, McClishe DK, Essah PA, Nestler JE: Association between current use of low-dose contraceptives and cardiovascular arterial disease: a meta-analysis. *J Clin Endocrinol Metab* 90:3863–3870, 2005
  26. Curtis KM, Chrisman CE, Peterson HB (WHO Programme for Mapping Best Practices in Reproductive Health): Contraception for women in selected circumstances. *Obstet Gynecol* 99:1100–1112, 2002
  27. Lidegaard Ø, Kreiner S: Contraceptives and cerebral thrombosis: a five-year national case-control study. *Contraception* 65:197–205, 2002
  28. Lidegaard Ø, Edström B, Kreiner S: Contraceptives and venous thromboembolism: a five-year national case-control study. *Contraception* 65:187–196, 2002
  29. Peterson KR, Skouby SO, Sidemann J, Molsted-Pedersen L, Jespersen J: Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. *Am J Obstet Gynecol* 171:400–405, 1994
  30. Garg SK, Chase HP, Marshal G, Hoops SL, Holmes DL, Jackson WE: Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. *JAMA* 271:1099–1102, 1994
  31. Klein BE, Moss SE, Klein R: Oral contraception in women with diabetes. *Diabetes Care* 13:8895–8898, 1990
  32. Ahmed S, Hovind P, Parving H-H, Rossing P, Price DA, Laffel LM, Lansang MC, Stevanovic R, Fisher NDL, Hollenberg NK: Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. *Diabetes Care* 28:1988–1994, 2005
  33. Damm P, Mathiesen E, Clausen TD, Pedersen KR: Contraception for women with diabetes mellitus. *Metabolic Syndrome and Related Disorders* 3:244–249, 2005
  34. Kjos SL: Optimal contraception for the diabetic woman. In *Textbook of Diabetes and Pregnancy*. Hod M, de Leiva A, Jovanovic L, Di Renzo, Langer O, Eds. London, Martin Dunitz, 2003, p. 589–596
  35. ACOG Practice Bulletin: The use of hormonal contraception in women with co-existing medical conditions. *Int J Gynecol Obstet* 75:93–106, 2001
  36. American Diabetes Association: Preconception care of women with diabetes (Position Statement). *Diabetes Care* 27 (Suppl. 1):S76–S78, 2004
  37. Skouby SO, Kuhl C, Molsted-Pedersen L, Petersen K, Christensen MS: Triphasic oral contraception: Metabolic effects in normal women and those with previous gestational diabetes. *Am J Obstet Gynecol* 153:495–500, 1985
  38. Kjos SL, Shoupe D, Douyan S, Freidman RL, Bernstein GS, Mestman JH, Mishell DR: Effect of low dose oral contraceptives on carbohydrate metabolism in women with recent gestational diabetes mellitus: results of a controlled, randomized, prospective study. *Am J Obstet Gynecol* 163: 1882–1827, 1990
  39. Skouby SO, Andersen O, Saubrey N, Kuhl C: Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes. *J Clin Endocrinol Metab* 64: 519–523, 1987
  40. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA: Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. *JAMA* 280:533–538, 1998
  41. Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D, Manson JE: A prospective study of oral contraceptives and NIDDM among U.S. women. *Diabetes Care* 20:330–335, 1997
  42. Creasy GW, Fisher AC, Hall N, Shangold

- GA: Transdermal contraceptive patch delivering noregestromin and ethinyl estradiol: effects on the lipid profile. *J Reprod Med* 48:179–186, 2003
43. Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, Nash HA: Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. *Contraception* 59:311–318, 1999
  44. Seaman HE, deVries CS, Farmer RDT: The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. *Hum Reprod* 18:522–526, 2003
  45. Wilson ES, Cruickshank J, McMaster M, Weir RJ: A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types of dosages and progestogen. *Br J Obstet Gynaecol* 91:1254–1260, 1984
  46. Liew DF, Ng CS, Yong YM, Ratnam SS: Long term effects of Depo-Provera on carbohydrate and lipid metabolism. *Contraception* 31:51–64, 1985
  47. Fahmy K, Abdel-Razik M, Shaaraway M, al-Kholy G, Saad S, Wagdi A, al-Azzony M: Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. *Contraception* 44:419–430, 1991
  48. Kahn HS, Curtis KM, Marchbanks PA: Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. *Diabetes Care* 26:216–225, 2003
  49. Singh K, Viegas OA, Koh SC, Ratnam SS: The effect of long-term use of Norplant implants on haemostatic function. *Contraception* 45:141–153, 1992
  50. Konje JC, Otolorin EO, Ladipo AO: The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. *Am J Obstet Gynecol* 166:15–19, 1992
  51. Suherman SK, Affandi B, Kovar T: The effects of Implanon on lipid metabolism in comparison with Norplant. *Contraception* 60:281–287, 1999
  52. Kim C, Seidel KW, Begier EA, Kwok YS: Diabetes and depot medroxyprogesterone contraception in Navajo women. *Arch Intern Med* 161:1766–1771, 2001
  53. Xiang AH, Kawakubo M, Kjos SL, Buchanan TA: Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. *Diabetes Care* 29:613–617, 2006